+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers



Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers



Journal of Clinical Pharmacology 34(11): 1109-1115



The pharmacokinetics of methylprednisolone were evaluated in 29 healthy volunteers after multiple intravenous doses of methylprednisolone sodium succinate or the novel prodrug, methylprednisolone suleptanate. Subjects were assigned randomly to one of four treatment groups (40, 100, 250, or 500 mg) and then randomly assigned to receive either the sodium succinate or suleptanate prodrugs. Doses were administered every 6 hours for 48 hours. Plasma and urine were assayed for methylprednisolone and unchanged prodrug using HPLC methods. Methylprednisolone pharmacokinetics exhibited both a dose and time dependency, which was similar for administration of both prodrugs. After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester. After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing. Apparent systemic clearance values determined after multiple dosing were 1.5- to 1.8-fold greater than corresponding first-dose values. No dependence on time was apparent for any prodrug pharmacokinetic parameter. These data suggest that the dose dependency of methylprednisolone pharmacokinetics is related to dose-dependent prodrug hydrolysis, whereas the time dependence possibly reflects auto-induction of methylprednisolone metabolism. Based on comparison of methylprednisolone pharmacokinetic parameters derived for each prodrug, methylprednisolone suleptanate resulted in a faster and slightly more efficient conversion to methylprednisolone than methylprednisolone sodium succinate.

(PDF emailed within 0-6 h: $19.90)

Accession: 009199133

Download citation: RISBibTeXText

PMID: 7876403

DOI: 10.1002/j.1552-4604.1994.tb01988.x


Related references

Comparative pharmacokinetics of methylprednisolone mp and its prodrugs following intravenous doses of methylprednisolone sodium succinate mpss and methylprednisolone suleptanate mpsp in humans. Clinical Pharmacology & Therapeutics 43(2): 189, 1988

Comparison of single and multiple dose pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone suleptanate. Clinical Pharmacology & Therapeutics 45(2): 148, 1989

Seventy-two hour comparison of methylprednisolone suleptanate and methylprednisolone sodium succinate in patients with acute asthma. British Journal of Clinical Practice 50(8): 440-445, 1996

Pharmacokinetics of methylprednisolone methylprednisolone sodium succinate and methylprednisolone acetate in dogs. Journal of Pharmaceutical Sciences 75(3): 251-255, 1986

Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. PharmacoTherapy 10(1): 29-34, 1990

Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 11(5): 377-379, 1988

Simultaneous analysis of dextran-methylprednisolone succinate, methylprednisolone succinate, and methylprednisolone by size-exclusion chromatography. Journal of Pharmaceutical & Biomedical Analysis 19(5): 785-792, 1999

Simultaneous analysis of dextran-methylprednisolone succinate, methylprednisolone succinate, and methylprednisolone by size-exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis 19(5): 785-792, 2000

Pharmacokinetics of methylprednisolone in cat plasma and spinal cord following a single intravenous dose of the sodium succinate ester. Drug Metabolism and Disposition: the Biological Fate of Chemicals 10(5): 551-552, 1982

Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: Dose-dependent pharmacokinetics in rats. International Journal of Pharmaceutics (Kidlington) 229(1-2): 173-182, 23 October, 2001

Pharmacokinetics of methylprednisolone succinate methylprednisolone and lidocaine in the normal dog and during hemorrhagic shock. Journal of Pharmaceutical Sciences 76(7): 528-534, 1987

Severe immunoglobulin E-mediated anaphylaxis to intravenous methylprednisolone succinate in a patient who tolerated oral methylprednisolone. Journal of Investigational Allergology and Clinical Immunology 19(4): 330-332, 2009

Effects of methylprednisolone suleptanate (U-6759OA) a new methylprednisolone analogue, on type I-IV allergic reactions and antibody formation. Pharmacometrics 46(3): 187-196, 1993

Effect of methylprednisolone and "pulse" therapy with methylprednisolone sodium succinate on autologous immune complex nephritis in rats. Journal of Pharmacobio-Dynamics 3(2): 117-122, 1980

Serum and urine methylprednisolone and methylprednisolone sodium succinate assay by a highly sensitive high performance liquid chromatography method. Clinical Chemistry 32(6): 1167, 1986